News | January 07, 2011

Study Shows Dietary Supplement Prevents Blood Vessel Blockage Process

January 7, 2011 – A new study from The Ohio State University found that Protandim can suppress intimal hyperplasia, the over-proliferation of cells that line the walls of blood vessels. The adverse blood vessel blockage often limits the effectiveness of several types of vascular surgery.

The study was sponsored by the American Heart Association and the National Institutes of Health, and was published in Free Radical Biology and Medicine.

Protandim is a dietary supplement from LifeVantage that is made up of five highly synergistic herbal ingredients. It had been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates the supplement’s ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes," which include most of the antioxidant enzymes.

Coronary artery bypass graft (CABG) surgery is performed more than 400,000 times a year in the United States. Most procedures requiring multiple bypasses still utilize the saphenous vein (taken from the leg) for secondary grafts. Ten years after CABG surgery, roughly half of the saphenous vein grafts often become largely – if not completely – blocked by processes that may result from intimal hyperplasia. Previous studies concluded that a major factor causing this condition is the three-to-five-fold higher concentration of oxygen experienced by the graft in its new environment.

In this study, Protandim significantly increased antioxidant enzyme activity in veins cultured at high oxygen. It also reduced free radical levels, lipid peroxidation and intimal proliferation to levels seen in a normal, healthy saphenous vein.

"This study was conducted in an ex vivo model using human saphenous veins harvested from patients undergoing bypass surgery - the exact population who might benefit from a therapy to prevent intimal hyperplasia," said Joe M. McCord, a co-author of the study.

For more information: www.LifeVantage.com

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init